During January we have done a few changes to our portfolio, our top 5 holdings are now the following:
We have slightly decreased our position in MGI and Embracer since our update. Nevertheless, we still think the R/R is still decent for both companies and we are likely at some point to increase them to our Top 5 holdings when we assess the opportunity arises again.
Two additions since our last update have been made Evolution Gaming Group and Maxcyte, you will find brief investment case summaries for both cases below:
1.Evolution is our top pick heading into February. We assess the company’s moat and long-term growth rate as highly misunderstood and often viewed upon with, in our view, undeserved skepticism.
2.We view the acquisition of NetEnt as a rare combination of revenue and margin expansion with tangible opportunities to leverage upon. It is our understanding that Evolution will further strengthen the offering and move more towards becoming a one-stop-shop for operators.
3.With the help of NetEnt’s offering, Evolution will be able to penetrate new markets faster. Furthermore, we assess that Evolution, who are known for their innovation, will infuse new life into NetEnt’s own product line.
1. A company that has been brewing just outside our Top-5 for some time now is the electroporation (EP) company MaxCyte. Modelio assesses it as one of the best investments to capture the growing gene editing and gene therapy space, especially in allogeneic ex-vivo treatments.
2. We estimate that MaxCyte stands before a huge inflection point that will accelerate both growth and profitability. We have seen signs of the accelerating underlying activity by the fact that they in the last two years have added 9 of their 12 commercial agreements.
3. What makes MaxCyte unique compared to other “pick-and-shovel” businesses is their claim to milestones and royalties, something usually reserved for pharmaceutical companies.
We close an eventful 2020 with an uneventful update of our list with our Top 5 holdings going into 2021. December saw renewed strength for our Swedish gaming holdings, with M8G advancing 38% and Embracer 12% respectively. Our Polish holding, 11 Bit Studios ended the month flat.
Photocure outperformed the market significantly at 35% for the month, and Smart Eye ended a strong 2020 with a 22% increase in December.
If you are interested in a deeper introduction to each case, we recommend our write-up from early December, which we have linked below.
11 Bit Studios S.A - In our opinion, 11 Bit is a high-conviction case, a rare high quality gaming developer with an exceptional track-record. We have previously described the case in a strongly recommended thorough report available here: slideshare.net/ModelioEquity/…
(2) We continue to reiterate our view on the case with a current fair value range of approx. 1400-1900 PLN per share (approx. 200-300% upside).
(3) The company has a proven and rare track-record platform to continue to build the growth journey. We assess at least one recurring (and increasingly larger) internal releases projects from 2023 and onwards.